Last reviewed · How we verify
Intensive BP treatment group — Competitive Intelligence Brief
phase 3
Cardiovascular
Small molecule
Live · refreshed every 30 min
Target snapshot
Intensive BP treatment group (Intensive BP treatment group) — China National Center for Cardiovascular Diseases. This is a treatment strategy that uses intensive blood pressure control to reduce cardiovascular events and mortality in hypertensive patients.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Intensive BP treatment group TARGET | Intensive BP treatment group | China National Center for Cardiovascular Diseases | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Intensive BP treatment group CI watch — RSS
- Intensive BP treatment group CI watch — Atom
- Intensive BP treatment group CI watch — JSON
- Intensive BP treatment group alone — RSS
Cite this brief
Drug Landscape (2026). Intensive BP treatment group — Competitive Intelligence Brief. https://druglandscape.com/ci/intensive-bp-treatment-group. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab